Cabazitaxel

Generic Name: Cabazitaxel

Brand Names: Jevtana, Cabazitaxel Accord

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₇NO_₁₄

CAS Number: 183133-96-2

Unique Ingredient Identifier: 51F690397J

Background: Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...

Indication: 用于治疗转移性去势抵抗性前列腺癌患者。

Associated Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Associated Therapies: -

Clinical Trials

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Phase 2

Active, not recruiting

Conditions: Prostate Cancer Aggressiveness
Prostate Carcinoma

Interventions: Drug: Cabazitaxel
Drug: Olaparib
Drug: Carboplatin
Drug: Prednisone 5Mg

First Posted Date: 2017-08-28

Last Posted Date: 2024-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 119

Registration Number: NCT03263650

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines

Phase 2

Conditions: Adrenocortical Carcinoma

Interventions: Drug: Cabazitaxel

First Posted Date: 2017-08-22

Last Posted Date: 2018-04-11

Lead Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Target Recruit Count: 25

Registration Number: NCT03257891

Locations: 🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy

A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis

Phase 2

Completed

Conditions: Penile Neoplasm

Interventions: Drug: Cabazitaxel

First Posted Date: 2017-04-14

Last Posted Date: 2022-11-18

Lead Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust

Target Recruit Count: 17

Registration Number: NCT03114254

Locations: 🇬🇧
Bristol Haematology and Oncology Centre, Horfield Road, Bristol, United Kingdom
🇬🇧
Universitty College Hospitals NHS Trust, London, United Kingdom

Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

Phase 2

Completed

Conditions: Circulating Tumor Cells
Chemotherapy
Prostate Carcinoma
Castration-resistant Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Docetaxel

First Posted Date: 2017-04-04

Last Posted Date: 2022-02-10

Lead Sponsor: UNICANCER

Target Recruit Count: 40

Registration Number: NCT03101046

Locations: 🇫🇷
ICO-Site René Gauducheau, Saint-Herblain, France
🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷
CHD Vendée, La Roche-sur-Yon, France

and more 2 locations

Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

Phase 2

Conditions: Circulating Tumor Cell
Metastatic Prostate Cancer

Interventions: Drug: Cabazitaxel
Other: Antihistamine
Other: Corticosteroid
Other: H2 antagonist
Other: Antiemetic

First Posted Date: 2017-02-13

Last Posted Date: 2021-08-20

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 140

Registration Number: NCT03050866

Locations: 🇳🇱
Franciscus Gasthuis en Vlietland, Rotterdam, Netherlands
🇳🇱
Groene Hart Ziekenhuis, Gouda, Netherlands
🇳🇱
Maasstad Ziekenhuis, Rotterdam, Netherlands

and more 6 locations

Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

Phase 2

Recruiting

Conditions: HER2 Negative Metastatic Breast Cancer

Interventions: Drug: Cabazitaxel
Drug: Paclitaxel

First Posted Date: 2017-02-09

Last Posted Date: 2019-11-13

Lead Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust

Target Recruit Count: 160

Registration Number: NCT03048942

Locations: 🇬🇧
Velindre Cancer Centre, Cardiff, United Kingdom
🇬🇧
Blackpool Victoria Hospital, Blackpool, United Kingdom
🇬🇧
Royal United Hospital, Bath, United Kingdom

and more 10 locations

Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel
Drug: Cabazitaxel
Drug: Clarithromycin

First Posted Date: 2017-02-06

Last Posted Date: 2020-02-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 4

Registration Number: NCT03043989

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-12-07

Last Posted Date: 2024-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 351

Registration Number: NCT02985957

Locations: 🇺🇸
Local Institution - 0078, Albany, New York, United States
🇺🇸
Local Institution - 0010, Philadelphia, Pennsylvania, United States
🇩🇰
Local Institution - 0063, Aarhus N, Midtjylland, Denmark

and more 56 locations

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Phase 3

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2016-11-10

Last Posted Date: 2022-05-12

Lead Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Target Recruit Count: 196

Registration Number: NCT02961257

Locations: 🇫🇷
CHU Henri-Mondor, Créteil, France
🇫🇷
Hôpital Universitaire Tenon, Paris, France
🇫🇷
Institut de Cancérologie du Gard - CHU, Nîmes, France

and more 28 locations

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Radium-223 dichloride
Drug: cabazitaxel
Drug: Carboplatin
Drug: Enzalutamide

First Posted Date: 2016-09-16

Last Posted Date: 2024-02-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 40

Registration Number: NCT02903160

Locations: 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy